

# Antonio Finelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9111869/publications.pdf>

Version: 2024-02-01

210  
papers

5,649  
citations

101543

36  
h-index

106344

65  
g-index

215  
all docs

215  
docs citations

215  
times ranked

8627  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. <i>British Journal of Radiology</i> , 2022, 95, 20210414.	2.2	11
2	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
3	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. <i>European Urology</i> , 2022, 81, 576-585.	1.9	21
4	Effect of <sup>18</sup> F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. <i>Radiology</i> , 2022, 303, 414-422.	7.3	16
5	Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. <i>Urology</i> , 2022, , .	1.0	2
6	A Novel Metric for Hospital Quality in Kidney Cancer Surgery: A Veterans Affairs National Health System Validation of Concept. <i>Urology Practice</i> , 2022, 9, 237-245.	0.5	1
7	Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	0
8	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. <i>European Radiology</i> , 2022, 32, 7544-7554.	4.5	8
9	Exploring the value of using patient-oriented MRI reports in clinical practice – a pilot study. <i>Supportive Care in Cancer</i> , 2022, 30, 6857-6876.	2.2	2
10	Impact of <sup>18</sup> F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. <i>Radiology</i> , 2022, 304, 600-608.	7.3	10
11	A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System. <i>Journal of Urology</i> , 2022, 208, 804-812.	0.4	2
12	Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. <i>European Urology Focus</i> , 2021, 7, 582-588.	3.1	10
13	Association between metformin medication, genetic variation and prostate cancer risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 96-105.	3.9	10
14	Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care. <i>European Urology Oncology</i> , 2021, 4, 494-497.	5.4	3
15	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
16	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021, 205, 78-85.	0.4	11
17	Reply By Authors. <i>Journal of Urology</i> , 2021, 205, 84-85.	0.4	0
18	Natural history of untreated kidney cancer. <i>World Journal of Urology</i> , 2021, 39, 2825-2829.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. <i>Prostate</i> , 2021, 81, 286-294.	2.3	4
20	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. <i>Canadian Urological Association Journal</i> , 2021, 15, E545-E552.	0.6	3
21	A systematic review and meta-analysis of unplanned hospital visits and re-admissions following radical prostatectomy for prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, E531-E544.	0.6	5
22	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. <i>Radiology</i> , 2021, 298, 695-703.	7.3	33
23	Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada. <i>BMJ Open</i> , 2021, 11, e045806.	1.9	12
24	Quantifying the "Assistant Effect" in Robotic-Assisted Radical Prostatectomy (RARP): Measures of Technical Performance. <i>Journal of Surgical Research</i> , 2021, 260, 307-314.	1.6	8
25	Comparison of Multiparametric Magnetic Resonance Imaging "Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 534.	7.1	99
26	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. <i>Journal of Urology</i> , 2021, 205, 1303-1309.	0.4	5
27	Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 371.e17-371.e25.	1.6	4
28	Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. <i>Urology</i> , 2021, , .	1.0	1
29	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , 2021, 153, 147-155.	1.0	5
30	High-intensity interval training or resistance training versus usual care in men with prostate cancer on active surveillance: a 3-arm feasibility randomized controlled trial. <i>Applied Physiology, Nutrition and Metabolism</i> , 2021, 46, 1535-1544.	1.9	11
31	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. <i>Journal of Urology</i> , 2021, 206, 1147-1156.	0.4	14
32	18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. <i>Current Oncology</i> , 2021, 28, 3251-3258.	2.2	2
33	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1156.	0.4	0
34	Optimizing the management of patients with small renal masses in a Canadian context: A Markov decision-analysis model. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	0
35	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , 2021, 300, 369-379.	7.3	34
36	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	1.9	49

#	ARTICLE	IF	CITATIONS
37	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 836.e19-836.e27.	1.6	9
38	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. <i>Nature Communications</i> , 2021, 12, 6248.	12.8	15
39	National consensus quality indicators to assess quality of care for active surveillance in low-risk prostate cancer: An evidence-informed modified Delphi survey of Canadian urologists/radiation oncologists. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	2
40	Cost-Effectiveness Analysis of Negative Pressure Wound Therapy to Prevent Surgical Site Infection after Elective Colorectal Surgery. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, .	1.3	1
41	Treatment on active surveillance of small renal masses: Progression vs. preference. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	3
42	Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 814228.	2.8	7
43	UPDATE " 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2021, 16, E184-96.	0.6	12
44	UPDATE " 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging " Summary of changes. <i>Canadian Urological Association Journal</i> , 2021, 16, 86-87.	0.6	1
45	Pfilates and Hypopressives for the Treatment of Urinary Incontinence After Radical Prostatectomy: Results of a Feasibility Randomized Controlled Trial. <i>PM and R</i> , 2020, 12, 55-63.	1.6	12
46	Causal variance decompositions for institutional comparisons in healthcare. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1972-1986.	1.5	3
47	Prognostic urinary miRNAs for the assessment of small renal masses. <i>Clinical Biochemistry</i> , 2020, 75, 15-22.	1.9	18
48	Searching for prognostic biomarkers for small renal masses in the urinary proteome. <i>International Journal of Cancer</i> , 2020, 146, 2315-2325.	5.1	21
49	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2020, 38, 2547-2554.	2.2	10
50	What are the limits of focal therapy for localized prostate cancer? For: GG3-5 may be considered. <i>European Urology Focus</i> , 2020, 6, 201-202.	3.1	3
51	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , 2020, 125, 525-530.	2.5	21
52	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	1.9	39
53	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
54	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. <i>Canadian Urological Association Journal</i> , 2020, 15, 132-137.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. <i>European Urology</i> , 2020, 78, 927-929.	1.9	2
56	Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. <i>European Urology</i> , 2020, 78, 460-467.	1.9	53
57	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. <i>European Urology Open Science</i> , 2020, 21, 1-4.	0.4	1
58	Determining Generalizability of the Canadian Kidney Cancer information system (CKCis) to the Entire Canadian Kidney Cancer Population. <i>Canadian Urological Association Journal</i> , 2020, 14, E499-E506.	0.6	13
59	Canadian Update on Surgical Procedures (CUSP) Urology Group consensus for intraoperative hemostasis during minimally invasive partial nephrectomy. <i>Canadian Urological Association Journal</i> , 2020, 14, E387-E393.	0.6	2
60	Learning from Our Past Mistakes: A Call for Randomized Controlled Trials in Localized Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 453-454.	5.4	0
61	Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. <i>Nature</i> , 2020, 586, 120-126.	27.8	249
62	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. <i>European Urology Open Science</i> , 2020, 22, 61-73.	0.4	11
63	[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. <i>BMJ Open</i> , 2020, 10, e035959.	1.9	8
64	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e17-603.e25.	1.6	14
65	Associations between self-reported physical activity, quality of life, and emotional well-being in men with prostate cancer on active surveillance. <i>Psycho-Oncology</i> , 2020, 29, 1044-1050.	2.3	8
66	Long-term outcomes after radical or partial nephrectomy for T1a renal cell carcinoma: A population-based study. <i>Canadian Urological Association Journal</i> , 2020, 14, 392-397.	0.6	3
67	Constructing inverse probability weights for institutional comparisons in healthcare. <i>Statistics in Medicine</i> , 2020, 39, 3156-3172.	1.6	4
68	Predictive Value of In Vivo MR Spectroscopy With Semilocalization by Adiabatic Selective Refocusing in Differentiating Clear Cell Renal Cell Carcinoma From Other Subtypes. <i>American Journal of Roentgenology</i> , 2020, 214, 817-824.	2.2	4
69	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e1-603.e7.	1.6	13
70	The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: Results from a large population-based cohort. <i>Canadian Urological Association Journal</i> , 2020, 14, 174-181.	0.6	13
71	Management of complex renal cysts in Canada: results of a survey study. <i>BMC Urology</i> , 2020, 20, 47.	1.4	5
72	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1085-1093.	0.4	44
74	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. <i>Journal of Urology</i> , 2020, 204, 476-482.	0.4	7
75	A Prospective Randomized Controlled Trial of Irrigation "Bag Squeeze" to Manage Pain for Patients Undergoing Flexible Cystoscopy. <i>Journal of Urology</i> , 2020, 204, 1012-1018.	0.4	9
76	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1187-1194.	0.4	9
77	Creating patient-centered radiology reports to empower patients undergoing prostate magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2020, 15, 108-113.	0.6	7
78	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 1093-1093.	0.4	0
79	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 1194-1194.	0.4	0
80	Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management. <i>World Journal of Urology</i> , 2019, 37, 437-443.	2.2	41
81	Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. <i>American Journal of Pathology</i> , 2019, 189, 2046-2060.	3.8	6
82	Influence of physical activity on active surveillance discontinuation in men with low-risk prostate cancer. <i>Cancer Causes and Control</i> , 2019, 30, 1009-1012.	1.8	5
83	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2019, 13, 307-314.	0.6	21
84	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database. <i>Canadian Urological Association Journal</i> , 2019, 14, 24-30.	0.6	2
85	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 576.e11-576.e16.	1.6	3
86	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 61-66.	0.8	8
87	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 88-96.	5.4	7
88	Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases. <i>Journal of Clinical Pathology</i> , 2019, 72, 363-367.	2.0	5
89	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e025662.	1.9	4
90	Magnetic resonance imaging diagnosis of prostate cancer: promise and caution. <i>Cmaj</i> , 2019, 191, E1177-E1178.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass. American Journal of Pathology, 2019, 189, 2366-2376.	3.8	12
92	Causal Mediation Analysis for Standardized Mortality Ratios. Epidemiology, 2019, 30, 532-540.	2.7	7
93	Metformin Use and Kidney Cancer Survival Outcomes. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 275-284.	1.3	6
94	&lt;p&gt;Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 10043-10050.	1.9	7
95	Renal Function Outcomes Following Radical or Partial Nephrectomy for Localized Renal Cell Carcinoma: Should Urologists Rely on Preoperative Variables to Predict Renal Function in the Long Term?. European Urology, 2019, 75, 773-774.	1.9	7
96	Needle Tract Seeding Following Renal Tumor Biopsy: Scarcely a Concern or a Concern to Scare?. European Urology, 2019, 75, 868-870.	1.9	6
97	Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. Journal of Urology, 2019, 201, 113-119.	0.4	57
98	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. Journal of Urology, 2019, 201, 284-291.	0.4	18
99	Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes. Journal of Urology, 2019, 202, 490-497.	0.4	9
100	Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. Journal of Urology, 2019, 202, 1159-1165.	0.4	8
101	A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.. Journal of Clinical Oncology, 2019, 37, 161-161.	1.6	0
102	Reply by Authors. Journal of Urology, 2019, 202, 1165-1165.	0.4	0
103	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e13-240.e20.	1.6	7
104	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 309-321.	1.9	51
105	Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?. Journal of Urology, 2018, 200, 731-736.	0.4	60
106	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. Journal of Urology, 2018, 200, 104-113.	0.4	41
107	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 702-709.	0.8	1
108	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. Journal of Urology, 2018, 199, 906-914.	0.4	22

#	ARTICLE	IF	CITATIONS
109	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , 2018, 199, 1182-1187.	0.4	22
110	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer – phase 1 trial. <i>European Radiology</i> , 2018, 28, 4281-4287.	4.5	30
111	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. <i>Journal of Urology</i> , 2018, 200, 283-291.	0.4	22
112	Psychological distress and lifestyle disruption in low-risk prostate cancer patients: Comparison between active surveillance and radical prostatectomy. <i>Journal of Psychosocial Oncology</i> , 2018, 36, 159-174.	1.2	11
113	Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 633-640.	0.4	57
114	Medication use and kidney cancer survival: A population-based study. <i>International Journal of Cancer</i> , 2018, 142, 1776-1785.	5.1	9
115	Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. <i>Journal of Urology</i> , 2018, 199, 251-256.	0.4	3
116	Challenges Interpreting Chemoprevention Studies Using Observational Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 628-629.	1.6	5
117	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3251-3258.	1.6	129
118	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 250-255.	0.6	3
119	Case – Foamy high-grade prostatic intraepithelial neoplasia: A false positive for prostate cancer on multiparametric magnetic resonance imaging?. <i>Canadian Urological Association Journal</i> , 2018, 12, E256-9.	0.6	2
120	Canadian consensus algorithm for erectile rehabilitation following prostate cancer treatment. <i>Canadian Urological Association Journal</i> , 2018, 13, 239-245.	0.6	7
121	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives. <i>Canadian Urological Association Journal</i> , 2018, 12, E210-8.	0.6	7
122	Low Testosterone and Prostate Cancer: Is the Protection Real?. <i>European Urology</i> , 2018, 74, 595-596.	1.9	2
123	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061.	0.4	2
124	Identifying the use and barriers to the adoption of renal tumour biopsy in the management of small renal masses. <i>Canadian Urological Association Journal</i> , 2018, 12, 260-266.	0.6	27
125	Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial. <i>Surgical Oncology</i> , 2018, 27, 289-298.	1.6	83
126	Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses. <i>JAMA Internal Medicine</i> , 2018, 178, 727.	5.1	1



#	ARTICLE	IF	CITATIONS
127	Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. Canadian Urological Association Journal, 2018, 12, 231-238.	0.6	14
128	Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. Molecular Oncology, 2018, 12, 1673-1688.	4.6	11
129	Statin use and time to progression in men on active surveillance for prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 509-515.	3.9	7
130	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
131	A miRNA-based classification of renal cell carcinoma subtypes by PCR and <i>in situ</i> hybridization. Oncotarget, 2018, 9, 2092-2104.	1.8	22
132	The impact of pre-cancer (Ca) diagnosis (Dx) psychiatric utilization (PU) on survival in patients with solid organ ca: A population analysis in Ontario, Canada.. Journal of Clinical Oncology, 2018, 36, e22144-e22144.	1.6	0
133	Editorial Comment. Journal of Urology, 2017, 197, 1013-1013.	0.4	0
134	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 668-680.	1.6	262
135	Active Surveillance Discussion for Low-risk Prostate Cancer: Patients' Preferences and Counseling Techniques. European Urology, 2017, 71, 872-873.	1.9	2
136	Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 52, 105-116.	7.7	53
137	Critical appraisal of the application of propensity score methods in the urology literature. BJU International, 2017, 120, 873-880.	2.5	9
138	The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study. European Urology, 2017, 72, 379-386.	1.9	19
139	miR-10b is a prognostic marker in clear cell renal cell carcinoma. Journal of Clinical Pathology, 2017, 70, 854-859.	2.0	29
140	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. BJU International, 2017, 120, 76-82.	2.5	23
141	The Association Between Vasectomy and Prostate Cancer. JAMA Internal Medicine, 2017, 177, 1273.	5.1	31
142	Medication use and kidney cancer risk: A population-based study. European Journal of Cancer, 2017, 83, 203-210.	2.8	11
143	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 604.e17-604.e24.	1.6	2
144	Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer. Annals of Internal Medicine, 2017, 167, 341.	3.9	35

#	ARTICLE	IF	CITATIONS
145	Diabetes and kidney cancer outcomes: a propensity score analysis. <i>Endocrine</i> , 2017, 55, 470-477.	2.3	8
146	Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 300-305.	1.9	17
147	Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. <i>BJU International</i> , 2017, 119, 543-549.	2.5	56
148	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. <i>Journal of Urology</i> , 2017, 197, 75-83.	0.4	39
149	Re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? <i>Eur Urol</i> 2016;70:403-406. <i>European Urology</i> , 2017, 71, e45-e46.	1.9	6
150	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. <i>CMAJ Open</i> , 2017, 5, E834-E841.	2.4	1
151	Active Surveillance in Small Renal Masses in the Elderly: A Literature Review. <i>European Urology Focus</i> , 2017, 3, 340-351.	3.1	29
152	CUA guideline on the management of cystic renal lesions. <i>Canadian Urological Association Journal</i> , 2017, 11, 66.	0.6	30
153	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017, 11, 182.	0.6	33
154	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. <i>Canadian Urological Association Journal</i> , 2017, 11, 232-7.	0.6	8
155	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , 2017, 11, 41.	0.6	11
156	The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 167.	0.6	6
157	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 42-42.	1.6	0
158	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. <i>Canadian Urological Association Journal</i> , 2016, 10, 424.	0.6	6
159	Appendix for: The uptake of active surveillance for the management of prostate cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 342.	0.6	1
160	The uptake of active surveillance for the management of prostate cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 333.	0.6	17
161	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016, 94, 154-160.	1.0	60
162	Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. <i>Pharmacological Research</i> , 2016, 113, 468-474.	7.1	19

#	ARTICLE	IF	CITATIONS
163	Statin use and kidney cancer outcomes: A propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 487.e1-487.e6.	1.6	16
164	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. <i>Journal of Urology</i> , 2016, 196, 1645-1650.	0.4	19
165	Multilocular Cystic Renal Cell Carcinoma: Pathological T Staging Makes No Difference to Favorable Outcomes and Should be Reclassified. <i>Journal of Urology</i> , 2016, 196, 1350-1355.	0.4	25
166	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e17-486.e23.	1.6	25
167	Surveillance of Small Renal Masses. <i>Urology</i> , 2016, 98, 8-13.	1.0	12
168	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e1-486.e7.	1.6	37
169	Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 226-230.	1.9	2
170	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. <i>Urology</i> , 2016, 93, 77-85.	1.0	31
171	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. <i>Journal of Urology</i> , 2016, 195, 307-312.	0.4	9
172	Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4 cm Can Be Offered Active Surveillance as an Initial Management Strategy. <i>European Urology</i> , 2016, 70, 85-90.	1.9	105
173	Active Surveillance for Renal Neoplasms with Oncocytic Features is Safe. <i>Journal of Urology</i> , 2016, 195, 581-587.	0.4	77
174	Should Prebiopsy Multiparametric Magnetic Resonance Imaging be Offered to All Biopsy-naïve Men Undergoing Prostate Biopsy?. <i>European Urology</i> , 2016, 69, 426-427.	1.9	7
175	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 25.	0.6	17
176	Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. <i>Canadian Urological Association Journal</i> , 2015, 9, 267.	0.6	11
177	Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. <i>Human Pathology</i> , 2015, 46, 673-680.	2.0	25
178	Management of Small Renal Mass: An Opportunity to Address a Growing Problem in Early Stage Kidney Cancer. <i>European Urology</i> , 2015, 68, 416-417.	1.9	8
179	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e7-386.e13.	1.6	31
180	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. <i>Journal of Urology</i> , 2015, 193, 1519-1524.	0.4	90

#	ARTICLE	IF	CITATIONS
181	Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. <i>European Urology</i> , 2015, 68, 1007-1013.	1.9	238
182	Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. <i>European Urology</i> , 2015, 67, 64-70.	1.9	91
183	Health-related quality of life in robotic versus open radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2015, 9, 179.	0.6	9
184	Canadian guidelines for the management of the small renal mass (SRM). <i>Canadian Urological Association Journal</i> , 2015, 9, 160.	0.6	45
185	Active surveillance in patients with a PSA $\geq$ 10 ng/mL. <i>Canadian Urological Association Journal</i> , 2014, 8, 702.	0.6	12
186	Routine small renal mass needle biopsy should be adopted. <i>Nature Reviews Urology</i> , 2014, 11, 548-549.	3.8	9
187	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. <i>Canadian Urological Association Journal</i> , 2014, 8, 47.	0.6	11
188	Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. <i>Journal of Clinical Oncology</i> , 2014, 32, 3892-3898.	1.6	84
189	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. <i>Canadian Urological Association Journal</i> , 2014, 8, 24.	0.6	44
190	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. <i>Urology</i> , 2014, 83, 81-87.	1.0	22
191	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. <i>Journal of Urology</i> , 2014, 192, 1088-1093.	0.4	6
192	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. <i>Urology</i> , 2014, 84, 1073-1080.	1.0	2
193	Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. <i>European Urology</i> , 2014, 66, 841-848.	1.9	56
194	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. <i>European Urology</i> , 2014, 66, 619-622.	1.9	57
195	Landmarks in the diagnosis and treatment of renal cell carcinoma. <i>Nature Reviews Urology</i> , 2014, 11, 517-525.	3.8	176
196	Chronic Kidney Disease in Patients With Renal Cell Carcinoma. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 91-95.	1.4	21
197	International Urology Journal Club via Twitter: 12-Month Experience. <i>European Urology</i> , 2014, 66, 112-117.	1.9	143
198	Lean Methodology Improves Efficiency in Outpatient Academic Uro-oncology Clinics. <i>Urology</i> , 2014, 83, 992-998.	1.0	33

#	ARTICLE	IF	CITATIONS
199	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 714-720.	0.4	22
200	Does gender influence morbidity or mortality in the surgical treatment of renal masses?. <i>Canadian Urological Association Journal</i> , 2014, 8, 311.	0.6	1
201	Assessing the effects of radiation on the small bowel. <i>Canadian Urological Association Journal</i> , 2013, 7, 449.	0.6	0
202	Robotic surgery basic skills training: Evaluation of a pilot multidisciplinary simulation-based curriculum. <i>Canadian Urological Association Journal</i> , 2013, 7, 430.	0.6	52
203	Improving outcomes through the development of quality indicators in renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 422-422.	1.6	0
204	Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 30-30.	1.6	1
205	High-dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. <i>FASEB Journal</i> , 2012, 26, 388.5.	0.5	0
206	A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15118-e15118.	1.6	0
207	Impact of 5 $\alpha$ -Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2011, 59, 509-514.	1.9	52
208	Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: long-term oncologic outcomes. <i>Current Opinion in Urology</i> , 2008, 18, 180-184.	1.8	7
209	Use of In-Biofilm Expression Technology To Identify Genes Involved in <i>Pseudomonas aeruginosa</i> Biofilm Development. <i>Journal of Bacteriology</i> , 2003, 185, 2700-2710.	2.2	70
210	Cryotherapy and radiofrequency ablation: pathophysiologic basis and laboratory studies. <i>Current Opinion in Urology</i> , 2003, 13, 187-191.	1.8	45